Companies
AstraZeneca
PharmaceuticalsCambridge, United KingdomAZN95,100 employees
More about AstraZeneca
Drugmaker that develops and sells prescription medicines in oncology, cardiovascular, renal, respiratory and rare diseases
Revenue
$58.7B
Fiscal 2025, up about 9%
Employees
95,100
As of December 2025
Stock
AZN
New York Stock Exchange
Headquarters
Cambridge, United Kingdom
CEO
Pascal Soriot
Since October 2012
BrandsTagrisso, Farxiga, Imfinzi, Enhertu, Alexion
Current strategyAiming for $80B in annual revenue and 20 new medicines by 2030; listed its ordinary shares directly on the NYSE in February 2026
CompetitorsPfizer, Novartis, Roche
Checked October 11, 2026 · Sources: sec.gov, astrazeneca.com
No source-backed updates for AstraZeneca yet. They appear here when a public report or filing covers the company.
No one has posted about AstraZeneca yet. Be the first to post ›
Follow AstraZeneca in a feed reader, no account needed: RSS feed